Catalyst Wire Dossier Catalyst Wire Dossier

Resiquimod topical gel 0.06%

Resiquimod · Spirig Pharma Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Resiquimod topical gel 0.06%, covering 2016-06-22 to 2016-06-22. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma [Phase 1, Phase 2]

See pricing